Migraine treatment

Migraine is a leading cause of disability, estimated to affect one-in-ten people in Spain. This study aimed to describe the management of migraine in Spain and identify improvement areas. Non-interventional, retrospective, cross-sectional cohort study conducted using an electronic medical records da...

ver descrição completa

Detalhes bibliográficos
Autores: Pozo-Rosich, Patricia|||0000-0003-0796-4702, Carmo, Mafalda, Muñiz, Alejandro, Armada, Beatriz, Moya-Alarcón, Carlota, Pascual Gómez, Julio|||0000-0002-3189-7573
Tipo de documento: artigo
Data de publicação:2024
País:España
Recursos:Universitat Autònoma de Barcelona
Repositório:Dipòsit Digital de Documents de la UAB
Idioma:inglês
OAI Identifier:oai:ddd.uab.cat:319984
Acesso em linha:https://ddd.uab.cat/record/319984
https://dx.doi.org/urn:doi:10.1186/s12883-024-03600-8
Access Level:Acceso aberto
Palavra-chave:Migraine
Management
Spain
Epidemiology
Acute
Preventive
Diagnosis
CGRP
Triptan
Patterns
id ES_c5f14ec9dafe55c1dd0b7414a4c4e2e0
oai_identifier_str oai:ddd.uab.cat:319984
network_acronym_str ES
network_name_str España
repository_id_str
spelling Migraine treatmentquo vadis ? Real-world data study (2015-2022) in SpainPozo-Rosich, Patricia|||0000-0003-0796-4702Carmo, MafaldaMuñiz, AlejandroArmada, BeatrizMoya-Alarcón, CarlotaPascual Gómez, Julio|||0000-0002-3189-7573MigraineManagementSpainEpidemiologyAcutePreventiveDiagnosisCGRPTriptanPatternsMigraine is a leading cause of disability, estimated to affect one-in-ten people in Spain. This study aimed to describe the management of migraine in Spain and identify improvement areas. Non-interventional, retrospective, cross-sectional cohort study conducted using an electronic medical records database covering visits to public healthcare providers for 3% of the Spanish population. Patients with a migraine diagnosis (ICD-9 346) between 01/2015 and 04/2022 were included, as well as their demographic and clinical characteristics, prescribed migraine treatments and the specialty of the prescribing physicians. The database included 61,204 patients diagnosed with migraine. A migraine treatment had been prescribed to 50.6% of patients over the last 24 months (only acute to 69.5%, both acute and preventive to 24.2%, and only preventive to 6.3%). The most frequently prescribed treatments were NSAIDs (56.3%), triptans (44.1%) and analgesics (28.9%). Antidepressants were the most common preventive treatment (prescribed to 17.9% of all treated patients and 58.7% of those treated with a preventive medication), and anti-CGRP monoclonal antibodies the least prescribed (1.7%; 5.7%). In 13.4% of cases, preventive medications were the first treatment: alone in 5.8% of cases and together with an acute medication in 7.6%. A fifth of patients who were initially prescribed with only acute treatment were later prescribed a preventive medication (20.7%). On average, it took 29.4 months for this change to occur. Two-thirds of patients started their preventive treatment in primary care (64.2%). The percentage of patients treated by a neurologist increased with the number of received preventive medications. However, 28.8% of patients who had already been prescribed five or more distinct preventive treatments were not treated by a neurologist. Migraine patients had between 1.2- and 2.2-times higher prevalence of comorbidities than the general population, age-gender adjusted. Our study emphasizes the need for improved management of migraine in Spain to reduce the risk of chronification and improve patient outcomes. More training and coordination across healthcare professionals is necessary to recognize and address risk factors for migraine progression, including multiple associated comorbidities and several lines of treatment, and to provide personalized treatment plans that address the complex nature of the condition. 22024-01-0120242024-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/319984https://dx.doi.org/urn:doi:10.1186/s12883-024-03600-8reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:3199842026-06-06T12:50:31Z
dc.title.none.fl_str_mv Migraine treatment
quo vadis ? Real-world data study (2015-2022) in Spain
title Migraine treatment
spellingShingle Migraine treatment
Pozo-Rosich, Patricia|||0000-0003-0796-4702
Migraine
Management
Spain
Epidemiology
Acute
Preventive
Diagnosis
CGRP
Triptan
Patterns
title_short Migraine treatment
title_full Migraine treatment
title_fullStr Migraine treatment
title_full_unstemmed Migraine treatment
title_sort Migraine treatment
dc.creator.none.fl_str_mv Pozo-Rosich, Patricia|||0000-0003-0796-4702
Carmo, Mafalda
Muñiz, Alejandro
Armada, Beatriz
Moya-Alarcón, Carlota
Pascual Gómez, Julio|||0000-0002-3189-7573
author Pozo-Rosich, Patricia|||0000-0003-0796-4702
author_facet Pozo-Rosich, Patricia|||0000-0003-0796-4702
Carmo, Mafalda
Muñiz, Alejandro
Armada, Beatriz
Moya-Alarcón, Carlota
Pascual Gómez, Julio|||0000-0002-3189-7573
author_role author
author2 Carmo, Mafalda
Muñiz, Alejandro
Armada, Beatriz
Moya-Alarcón, Carlota
Pascual Gómez, Julio|||0000-0002-3189-7573
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv Migraine
Management
Spain
Epidemiology
Acute
Preventive
Diagnosis
CGRP
Triptan
Patterns
topic Migraine
Management
Spain
Epidemiology
Acute
Preventive
Diagnosis
CGRP
Triptan
Patterns
description Migraine is a leading cause of disability, estimated to affect one-in-ten people in Spain. This study aimed to describe the management of migraine in Spain and identify improvement areas. Non-interventional, retrospective, cross-sectional cohort study conducted using an electronic medical records database covering visits to public healthcare providers for 3% of the Spanish population. Patients with a migraine diagnosis (ICD-9 346) between 01/2015 and 04/2022 were included, as well as their demographic and clinical characteristics, prescribed migraine treatments and the specialty of the prescribing physicians. The database included 61,204 patients diagnosed with migraine. A migraine treatment had been prescribed to 50.6% of patients over the last 24 months (only acute to 69.5%, both acute and preventive to 24.2%, and only preventive to 6.3%). The most frequently prescribed treatments were NSAIDs (56.3%), triptans (44.1%) and analgesics (28.9%). Antidepressants were the most common preventive treatment (prescribed to 17.9% of all treated patients and 58.7% of those treated with a preventive medication), and anti-CGRP monoclonal antibodies the least prescribed (1.7%; 5.7%). In 13.4% of cases, preventive medications were the first treatment: alone in 5.8% of cases and together with an acute medication in 7.6%. A fifth of patients who were initially prescribed with only acute treatment were later prescribed a preventive medication (20.7%). On average, it took 29.4 months for this change to occur. Two-thirds of patients started their preventive treatment in primary care (64.2%). The percentage of patients treated by a neurologist increased with the number of received preventive medications. However, 28.8% of patients who had already been prescribed five or more distinct preventive treatments were not treated by a neurologist. Migraine patients had between 1.2- and 2.2-times higher prevalence of comorbidities than the general population, age-gender adjusted. Our study emphasizes the need for improved management of migraine in Spain to reduce the risk of chronification and improve patient outcomes. More training and coordination across healthcare professionals is necessary to recognize and address risk factors for migraine progression, including multiple associated comorbidities and several lines of treatment, and to provide personalized treatment plans that address the complex nature of the condition.
publishDate 2024
dc.date.none.fl_str_mv 2
2024-01-01
2024
2024-01-01
dc.type.none.fl_str_mv Article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/319984
https://dx.doi.org/urn:doi:10.1186/s12883-024-03600-8
url https://ddd.uab.cat/record/319984
https://dx.doi.org/urn:doi:10.1186/s12883-024-03600-8
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869419031305388032
score 15,812429

Registros relacionados